Personalized 4-week nutrition and activity program for people after esophageal cancer surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Participants will receive a 4-week, theory-based ecological nutrition intervention tailored to individual post-esophagectomy needs, including written nutrition guidelines, customized care foods, a wearable device to encourage walking, and weekly telephone counseling. Outcomes measured before and after the program include food intake, adherence to dietary guidance, activity level, nutritional indices (such as PNI and NRI), weight change, fatigue, symptom burden, quality of life, and satisfaction with meals and services. The study also includes post-intervention interviews to capture patient experiences and assess clinical feasibility. The approach emphasizes practical, individualized supports to address common nutritional and functional challenges after esophageal cancer surgery.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with clinical stage 1-3 primary esophageal cancer at diagnosis who have planned or received treatment, including esophageal resection and reconstruction, with curative intent, and their families\*.
* You are at least 18 years of age
* Have a native-level understanding of Korean
* Who consented to this study

Exclusion Criteria:

* Concurrent multiple cancers at the time of diagnosis or a history of diagnosed and treated other organ cancers within the past year at the time of diagnosis
* Have had esophageal resection and reconstruction surgery for other reasons before being diagnosed with esophageal cancer
* Persons with limited cognitive and communication abilities
* The patient has had problems progressing to oral feeding after surgery, requiring a concurrent ileostomy, or the investigator determines that an interventional study is not appropriate.
* Individuals with reduced renal function for whom protein intake is not recommended (estimated GFR \<60 mL/min/1.73 m2)
* People who are unable to walk due to joint problems, paralysis, etc.
* Those who do not use smartphones

Where it's running

• Samsung Medical Center
  Seoul, Seoul, South Korea Recruiting

Study contacts

• Principal investigator: Juhee Cho, PhD — Samsung Medical Center
• Study coordinator: Juhee Cho, PhD
• Email: alfadur2j@gmail.com
• Phone: +8234101448

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PF-08098488 in adults with advanced solid tumors

  This study tests PF-08098488 in adults whose cancer has progressed or returned after prior treatment.

  Recruiting at 4 sites Phase 1 Pfizer · Grand Rapids, Michigan and 3 other locations · NCT07903415

• Modular Robot-Assisted Esophagectomy vs. Conventional Minimally Invasive Esophagectomy for Esophageal Cancer

  This trial tests whether modular robotic-assisted esophagectomy using the Carina platform works better than conventional 3D thoracoscopic esophagectomy for people with resectable esophageal cancer.

  Recruiting Phase 3 Ruijin Hospital · Shanghai · NCT07888140

• MGC030 in adults with advanced solid tumors

  This trial tests MGC030 in adults with advanced urothelial, gastric/GEJ, esophageal, colorectal, gastric, pancreatic, or GEJ cancers to see if it is safe and whether it can shrink tumors or stop growth.

  Recruiting Phase 1 MacroGenics · Lake Success, New York · NCT07822399

• Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer

  This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.

  Recruiting at 7 sites Phase 1/2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07818018

• TS-104: a first-in-human, dose-escalation study for advanced solid tumors

  This study tests TS-104, a peptide-drug conjugate, as a single therapy in adults with advanced solid tumors like NSCLC, HNSCC, esophageal, gastric, ovarian, or endometrial cancer to see if it is safe and tolerable and whether it shows any benefit.

  Recruiting at 3 sites Phase 1 TwoStep Therapeutics, Inc. · Maumee, Ohio and 2 other locations · NCT07814248

• First-in-human STRO-006 in adults with certain recurrent or metastatic solid tumors

  This study tests STRO-006 alone and with pembrolizumab in adults with certain head and neck, lung, esophageal, gastric, colorectal cancers to see if it is safe and shows early anticancer activity.

  Recruiting at 3 sites Phase 1 Sutro Biopharma, Inc. · Orlando, Florida and 5 other locations · NCT07807345

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.